While the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the treatment of diabetes in patients with CKD recommend SGLT2 inhibitors as the first-line therapy [11], the KDIGO guideline for glomerular disease management, published in 2021, did not recommend the utilization of SGLT2 inhibitors in IgA nephropathy (IgAN) without diabetes [12]. Here, SLC5A2 is linked to chronic kidney disease.